Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01713504
Other study ID # 2008_29
Secondary ID 2009-A00314-53
Status Completed
Phase N/A
First received
Last updated
Start date June 29, 2010
Est. completion date July 2015

Study information

Verified date February 2019
Source University Hospital, Lille
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative and more accessible compared to those that we have already thanks to a proteomic approach. This will help the investigators to diagnose the this disease.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- dated and signed informed consent

- virale serology negative or negative result less than 6 months

- virale serology negative for HBV or vaccinated patient

- insured

- virale serology negative or negative result less than 6 months

- negative pregnancy test or female menopause for at least 1 year

Exclusion Criteria:

- subject enable adult, under guardianship or under protective measures of justice

- Refusal or inability to give informed consent

- The hypereosinophilic syndrome explained origin other than than atopy, bullous pemphigoid, the Churg-Strauss syndrome and DRESS

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
biologie sample
comparison of biomarkers between HES, HE biomarkers data and control arms

Locations

Country Name City State
France CHRU, Hôpital Claude Huriez Lille Nord

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Lille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The aim is to characterize, through an approach immunoprotéomique, new HES biomarkers more informative and easier access than those currently available to us. These biomarkers will help to the diagnosis of HES, compared with other causes of eosinophilia. one month after patient inclusion
See also
  Status Clinical Trial Phase
Recruiting NCT05334368 - Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial Phase 3
Recruiting NCT00044304 - Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome Phase 2
Completed NCT00097370 - Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome Phase 3
Completed NCT00171912 - Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Phase 2
Terminated NCT00171860 - A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome Phase 2
Recruiting NCT02581514 - Eosinophilia Diagnosis N/A
Completed NCT00787384 - Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Phase 2
Recruiting NCT03801434 - Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Phase 2
Completed NCT00255346 - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Phase 2
Completed NCT03306043 - A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 Phase 3
Recruiting NCT04018118 - Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
Completed NCT02836496 - Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Phase 3
Completed NCT00086658 - Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) Phase 3
Recruiting NCT00276926 - Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Phase 2
Active, not recruiting NCT02101138 - Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome Phase 2
Recruiting NCT00091871 - A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Completed NCT00038675 - Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate N/A
Completed NCT00017862 - Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Phase 2
Terminated NCT00230334 - Phase II Gleevec Idiopathic Hypereosinophilic Syndrome Phase 2
Recruiting NCT04191304 - A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) Phase 3